Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma—a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology
Authors:
- Giulia MarvasoGMGiulia Marvaso
- Barbara Alicja Jereczek-FossaBJBarbara Alicja Jereczek-Fossa
- Mattia ZaffaroniMZMattia Zaffaroni
- Maria Giulia VinciniMVMaria Giulia Vincini
- Giulia CorraoGCGiulia Corrao
- Nicolaus AndratschkeNANicolaus Andratschke
- Ehsan H BalagamwalaEBEhsan H Balagamwala
- Jens BedkeJens Bedke
- Oliver BlanckOBOliver Blanck
- Umberto CapitanioUCUmberto Capitanio
- Rohann J M CorreaRCRohann J M Correa
- Gert De MeerleerGMGert De Meerleer
- 29 April 2024
- journal article
- review article
- Published by Elsevier in The Lancet Oncology
- Vol. 25 (5) , e193-e204
Abstract
No abstract availableKeywords
Funding Information
- Royal Marsden NHS Foundation Trust (A28724)
- Cancer Research UK (C33589/A28284)
- Ministero della Salute (5\u2008\u00D7\u20081000)
- Institute of Cancer Research
- Cancer Council Tasmania
- Istituto Europeo di Oncologia
- National Institute for Health and Care Research
- Associazione Italiana per la Ricerca sul Cancro
This publication has 39 references indexed in Scilit:
- The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic ReviewEuropean Urology Focus, 2022
- The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study groupClinical & Experimental Metastasis, 2021
- Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II)JAMA Oncology, 2021
- Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensusCancer Treatment Reviews, 2021
- Biomarkers in renal cell carcinoma: Are we there yet?Asian Journal of Urology, 2021
- Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?Clinical and Translational Oncology, 2021
- Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation StudyClinical Genitourinary Cancer, 2021
- Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?Current Urology Reports, 2019
- Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studiesEuropean Urology Oncology, 2019
- Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CTAnnals of Nuclear Medicine, 2019